NCT02640820

Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)

A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts) in Subjects Ages 18 - 65 Years

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 83 (actual)
• Sponsor: RXi Pharmaceuticals, Corp. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Warts are benign epidermal tumors caused by human papillomaviruses (HPVs). The active pharmaceutical ingredient DPCP has been used for many years as a compounded formulation in acetone for the treatment of warts, alopecia areata and more recently, cutaneous metastatic melanoma lesions. An improved topical ointment formulation of DPCP called Samcyprone™ will be evaluated for the treatment of common warts.

Conditions

• Common Warts
• HPV (Human Papillomavirus)
• Periungual Warts
• Plantar Warts

Interventions

Type	Name	Description
DRUG	Sensitizing DPCP Ointment	Sensitization
DRUG	Treatment DPCP Ointment	Treatment

Timeline

• Start date: 2015-12-01
• Primary completion: 2018-01-01
• Completion: 2018-05-01
• First posted: 2015-12-29
• Last updated: 2018-02-23

Locations

4 sites across 1 country: United States